Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07152782 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

Name: T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis — clinical trial record (NCT07152782)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: THUNDER

StatusRecruiting

PhasePhase 2

SponsorFudan University

Started2025-09-24

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 20 months later Nov 2027 → Aug 2029

See other at-risk trials from Fudan University

Amendment history

2026-09-29

Recruitment opened

Primary completion pushed: 2027-11 → 2029-08

Completion pushed: 2029-11 → 2031-11

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis

Trial Details

NCT Number	NCT07152782
Lead Sponsor	Fudan University
Conditions	Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
Enrollment	202 participants
Start Date	2025-09-24
Primary Completion	2029-08 (estimated)
Study Completion	2031-11 (estimated)
Updated on ClinicalTrials.gov	2026-09-28